These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 18487514)

  • 1. Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide].
    Satow A; Maehara S; Ise S; Hikichi H; Fukushima M; Suzuki G; Kimura T; Tanak T; Ito S; Kawamoto H; Ohta H
    J Pharmacol Exp Ther; 2008 Aug; 326(2):577-86. PubMed ID: 18487514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
    Suzuki G; Kimura T; Satow A; Kaneko N; Fukuda J; Hikichi H; Sakai N; Maehara S; Kawagoe-Takaki H; Hata M; Azuma T; Ito S; Kawamoto H; Ohta H
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1144-53. PubMed ID: 17360958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
    Satow A; Suzuki G; Maehara S; Hikichi H; Murai T; Murai T; Kawagoe-Takaki H; Hata M; Ito S; Ozaki S; Kawamoto H; Ohta H
    J Pharmacol Exp Ther; 2009 Jul; 330(1):179-90. PubMed ID: 19359526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
    Galici R; Jones CK; Hemstapat K; Nong Y; Echemendia NG; Williams LC; de Paulis T; Conn PJ
    J Pharmacol Exp Ther; 2006 Jul; 318(1):173-85. PubMed ID: 16608916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
    Kinney GG; O'Brien JA; Lemaire W; Burno M; Bickel DJ; Clements MK; Chen TB; Wisnoski DD; Lindsley CW; Tiller PR; Smith S; Jacobson MA; Sur C; Duggan ME; Pettibone DJ; Conn PJ; Williams DL
    J Pharmacol Exp Ther; 2005 Apr; 313(1):199-206. PubMed ID: 15608073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents.
    Hikichi H; Murai T; Okuda S; Maehara S; Satow A; Ise S; Nishino M; Suzuki G; Takehana H; Hata M; Ohta H
    Eur J Pharmacol; 2010 Aug; 639(1-3):106-14. PubMed ID: 20371227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors.
    Chen Y; Goudet C; Pin JP; Conn PJ
    Mol Pharmacol; 2008 Mar; 73(3):909-18. PubMed ID: 18056795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological effects of metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice.
    Hikichi H; Nishino M; Fukushima M; Satow A; Maehara S; Kawamoto H; Ohta H
    Eur J Pharmacol; 2010 Aug; 639(1-3):99-105. PubMed ID: 20371235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition.
    Pietraszek M; Gravius A; Schäfer D; Weil T; Trifanova D; Danysz W
    Neuropharmacology; 2005 Jul; 49(1):73-85. PubMed ID: 15992582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of defensive responses and anxiety-like behaviors by group I metabotropic glutamate receptors located in the dorsolateral periaqueductal gray.
    Lima VC; Molchanov ML; Aguiar DC; Campos AC; Guimarães FS
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):178-85. PubMed ID: 17804134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists.
    Suzuki G; Kawagoe-Takaki H; Inoue T; Kimura T; Hikichi H; Murai T; Satow A; Hata M; Maehara S; Ito S; Kawamoto H; Ozaki S; Ohta H
    J Pharmacol Sci; 2009 Jul; 110(3):315-25. PubMed ID: 19542684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
    Lindemann L; Jaeschke G; Michalon A; Vieira E; Honer M; Spooren W; Porter R; Hartung T; Kolczewski S; Büttelmann B; Flament C; Diener C; Fischer C; Gatti S; Prinssen EP; Parrott N; Hoffmann G; Wettstein JG
    J Pharmacol Exp Ther; 2011 Nov; 339(2):474-86. PubMed ID: 21849627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats.
    Pietraszek M; Sukhanov I; Maciejak P; Szyndler J; Gravius A; Wisłowska A; Płaźnik A; Bespalov AY; Danysz W
    Eur J Pharmacol; 2005 May; 514(1):25-34. PubMed ID: 15878321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning.
    Jacob W; Gravius A; Pietraszek M; Nagel J; Belozertseva I; Shekunova E; Malyshkin A; Greco S; Barberi C; Danysz W
    Neuropharmacology; 2009 Aug; 57(2):97-108. PubMed ID: 19426746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CFMTI, an allosteric metabotropic glutamate receptor 1 antagonist with antipsychotic activity, on Fos expression in regions of the brain related to schizophrenia.
    Suzuki G; Satow A; Ohta H
    Neuroscience; 2010 Jul; 168(3):787-96. PubMed ID: 20399255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease.
    Dekundy A; Pietraszek M; Schaefer D; Cenci MA; Danysz W
    Brain Res Bull; 2006 Apr; 69(3):318-26. PubMed ID: 16564428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postsynaptic and presynaptic group II metabotropic glutamate receptor activation reduces neuronal excitability in rat midline paraventricular thalamic nucleus.
    Hermes ML; Renaud LP
    J Pharmacol Exp Ther; 2011 Mar; 336(3):840-9. PubMed ID: 21139059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the metabotropic glutamate receptor mGluR5 prevents glutamate toxicity in primary cultures of cerebellar neurons.
    Montoliu C; Llansola M; Cucarella C; Grisolía S; Felipo V
    J Pharmacol Exp Ther; 1997 May; 281(2):643-7. PubMed ID: 9152368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain.
    O'Brien JA; Lemaire W; Wittmann M; Jacobson MA; Ha SN; Wisnoski DD; Lindsley CW; Schaffhauser HJ; Rowe B; Sur C; Duggan ME; Pettibone DJ; Conn PJ; Williams DL
    J Pharmacol Exp Ther; 2004 May; 309(2):568-77. PubMed ID: 14747613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1.
    Kohara A; Toya T; Tamura S; Watabiki T; Nagakura Y; Shitaka Y; Hayashibe S; Kawabata S; Okada M
    J Pharmacol Exp Ther; 2005 Oct; 315(1):163-9. PubMed ID: 15976016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.